德国Viatris开发的药物吸入器满足哮喘治疗需求

 
2005年9月丹麦哥本哈根举行的欧洲呼吸学会年度大会上，广大医生呼吁开发更加有效的输送设备以治疗哮喘患者。

大多数哮喘患者不能正确使用他们的吸入器，而且大多数患者对他们的治疗方案并不依从。伦敦Guy医学院、King医学院、St.Thomas医学院呼吸医学和过敏反应系的Brian O'Connor医生说：“为了帮助患者，治疗方案应当简单；应当说服患者有效地接受治疗，给药方案应当尽可能的最少。最重要的是，确保患者能够正确使用吸入器。”

近些年用于治疗哮喘的基本治疗药物几乎没有什么改变。发生改变的是用于输送药物的设备。尽管经过有效的培训与咨询，患者仍然面临困难。使用设备通常需要良好的手动－呼吸协调性。出席会议的医生评估了一种干粉吸入器（DPI），这种新型设备是专门开发用于正确而简单的操作，确保将足量的药物送入肺部。

这种新型可灌装设备叫做Novolizer，使用气旋作用将颗粒解凝聚，以确保药物在肺脏的有效分布。该设备设计比目前日常使用的其他设备更加容易操作，特别适合儿童和老人使用。Novolizer目前在英国获得批准应用。该设备是由德国Viatris Pharmaceuticals GmbH (Bad Homburg, Germany)公司研制开发的。

Asthmatics Need Better Delivery Devices
 
During the annual congress of the European Respiratory Society (ERS), held in Copenhagen (Denmark) in September 2005, clinicians called for more efficient delivery devices for asthma patients.

Most asthma patients cannot use their inhalers correctly and many are noncompliant with their treatment regimens. “To help patients, the treatment plan should be kept simple, the patient should be persuaded of the effectiveness of the treatment, and the dosing regimen should be minimized as much as possible,” said Dr. Brian O’Connor, department of respiratory medicine and allergy, Guy’s, King’s, and St. Thomas’ School of Medicine in London (UK). “Most importantly of all, ensure that the patient can use the inhalers correctly.”

Basic medication used to treat asthma has changed little over the years. What has changed are the numerous devices used to deliver the medications. Despite effective training and counseling, patients are still experiencing problems. Using a device usually requires good hand-breath coordination. Clinicians at the meeting evaluated a new dry powder inhaler (DPI), a novel delivery device that has been specifically developed to be easy to use correctly and ensure deposition of sufficient medication to the lungs.

The new refillable device, called Novolizer, uses a cyclone effect for particle deagglomeration in order to achieve effective lung deposition. It is designed to be easier to operate than many other devices in daily practice, making it easy for children and the elderly to use. The Novolizer is currently approved for use in the United Kingdom for budesonide. The device was developed by Viatris Pharmaceuticals GmbH (Bad Homburg, Germany).